80 news items
Page 3 of 4
hvgk64k02jjz42p56y4v7c gs0drndq027mbj
ADSK
CKPT
PERI
2 May 24
for curative surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL
9nsfryo 2ph
CKPT
2 May 24
"that the [FDA] has issued a complete response letter (‘CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced
55slkmsxgx3krgm3ahwlwgo5lo38ne8ubek0cr9ejrl5bix5dzdegkvc
CKPT
1 May 24
, the Company stated that the FDA had issued a complete response letter which "cites findings that arose during a multi-sponsor inspection of Checkpoint's
kkezph1wq5gvw2dsd rbrwjx3v
CKPT
1 May 24
are not candidates for curative surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL
0prb048rilkzm5tlxzfaha6h7
CKPT
29 Apr 24
, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients
n2j8vlf99nfjm
ADSK
CKPT
PERI
28 Apr 24
or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL') for the cosibelimab [BLA
jlr mzrt9j453ea64hbpbz0j7aml1
CKPT
28 Apr 24
a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who
kbwb9yg3 3k7o5b6tuyysswwd1uxfm
CKPT
26 Apr 24
issued a complete response letter (‘CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who
rhacjtdu790bv9hqf9ax7dj0vyp5146gmzd z0wg1gqf7w7
CKPT
PERI
SOND
24 Apr 24
a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who
9sc1ggfgssg76arlxiolks9w0
CKPT
24 Apr 24
"that the [FDA] has issued a complete response letter (‘CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally
esj99jnbn7aboobua8mlh2141ipvkjrx68sr0ntaeda2ake4
CKPT
23 Apr 24
for curative surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL
fek9wyf9med8h0cj02rchna0h55s0p53afqjjflazb2tvdnxt5lxv54bn
CKPT
22 Apr 24
, the Company stated that the FDA had issued a complete response letter which "cites findings that arose during a multi-sponsor inspection of Checkpoint's
oc4up6cpno148604vpbzzvs87lajwzucxy9c
AVXL
CKPT
VTYX
20 Apr 24
] has issued a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced
821ofq3ai0sjhur09gkaan 0xk8o
CKPT
20 Apr 24
a complete response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who
bw4j2uvoxp1i
CKPT
19 Apr 24
that the FDA had issued a complete response letter which "cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO
ql1bfq283k3jpchzjsbycev66or8s0t1utbk6a
CKPT
18 Apr 24
cSCC who are not candidates for curative surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response
3s7fj4 qaj79qfchpb61pxiril2gosk02l
CKPT
17 Apr 24
cutaneous squamous cell carcinoma ("cSCC") treatment, cosibelimab. Specifically, the Company stated that the FDA had issued a complete response letter
l63t p6eaoj00yw24qxuw2
CKPT
17 Apr 24
are not candidates for curative surgery or radiation. In particular, the Company announced "that the [FDA] has issued a complete response letter ('CRL
ofvowrv4t8deycq 7lbw8g
AVXL
CKPT
SOND
16 Apr 24
response letter ('CRL') for the cosibelimab [BLA] for the treatment of patients with metastatic or locally advanced [cSCC] who are not candidates
mmcyanrs0f9c 0ij4
CKPT
16 Apr 24
("cSCC") treatment, cosibelimab. Specifically, the Company stated that the FDA had issued a complete response letter which "cites findings that arose